NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Core Points - NuCana plc will present at the ESMO Congress 2025, focusing on the synergy between NUC-7738 and PD-1 inhibition in renal cell cancer [1] - The presentation is scheduled for October 19, 2025, and will be part of the Investigational Immunotherapy session [1] - NuCana is a clinical-stage biopharmaceutical company utilizing ProTide technology to enhance chemotherapy agents [3] Company Overview - NuCana aims to improve cancer treatment outcomes by transforming nucleoside analogs into more effective and safer medicines [3] - The company's pipeline includes NUC-7738, which is in Phase 2 of a Phase 1/2 study, and NUC-3373, currently in a Phase 1b/2 modular study [3] - NUC-7738 targets multiple aspects of the tumor microenvironment and disrupts RNA polyadenylation [3]